AMS NEWS

CDC Health Advisory: Increases in Fentanyl Drug Confiscations

Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities Summary The Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA) are investigating recent increases in fentanyl-related unintentional overdose fatalities in multiple states across the U.S. The purpose of this HAN advisory is to: (1)…

Hydrocodone Reclassification: What physicians need to know

Recently, the Drug Enforcement Administration (DEA) issued a final rule rescheduling hydrocodone combination products (HCPs) into Controlled Substance Schedule II, effective October 6, 2014.   Rescheduling issues directly related to Arkansas: Under Arkansas law, physician assistants and advance practice registered nurses are not authorized to write prescriptions for…

New Information On Acetaminophen

FDA Acetaminophen Limits in Combination Products   Effective January 14, 2014, it will become unlawful to purchase or sell any narcotic/acetaminophen combination products that contain greater than 325mg of acetaminophen.  This ban on high dosage acetaminophen in prescription combination products was first passed by the FDA in January 2011. …

FDA Warns Oral Anti-Fungal May Cause Adrenal, Liver Problems

The Wall Street Journal (7/27, Burton, Subscription Publication, 2.29M) reported that the US Food and Drug Administration announced Friday that it was limiting the use of Johnson & Johnson's oral, anti-fungal therapy, Nizoral (ketoconazole). Although the product is available as a topical, including as a cream and a…

FDA Drug Alert Issued

An important FDA-approved Drug Alert for INVIRASE affecting Cardiology, Infectious Disease, Internal Medicine, Pediatrics, Nurse Practitioners, and Pharmacies was published on February 28, 2013. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within this specialty who are registered with PDR® Network. To ensure…

FDA Drug Alert Issued for Xeljanz

An important FDA-approved Drug Alert for XELJANZ affecting Rheumatologists, Infectious Disease, Family Medicine/General Practice, Internal Medicine and  Emergency Medicine physicians was published on November 20, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered with PDR® Network. View…

FDA-approved Drug Alert Issued

An important FDA-approved Drug Alert for BONIVA affecting Family Medicine/General Practitioners, Internal Medicine, Endocrinology, Diabetes & Metabolism and Obstetrics & Gynecology was published on October 1, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered with PDR®…